[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620718":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":29,"locations":39,"responsibleParty":66,"collaborators":11,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":11,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":42,"whyStopped":11,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"University Hospital, Basel, Switzerland","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"estradiol valerate","EXPERIMENTAL",null,[13],"Drug: estradiol valerate",{"label":15,"type":10,"description":11,"interventionNames":16},"esthinylestradiol",[17],"Drug: esthinylestradiol",[19,22],{"type":20,"name":9,"description":9,"armGroupLabels":21,"otherNames":11},"DRUG",[9],{"type":20,"name":15,"description":9,"armGroupLabels":23,"otherNames":11},[15],[25],{"name":26,"affiliation":27,"role":28},"Mirjam Christ-Crain, Prof. Dr.","University Hospital of Basel","STUDY_CHAIR",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Andi Nikaj, MD","CONTACT","+41 61 328 57 43","andi.nikaj@usb.ch",{"name":36,"role":32,"phone":37,"phoneExt":11,"email":38},"Ursula Gobrecht-Keller, MD","+41 61 32 86028","ursula.gobrecht@usb.ch",[40],{"facility":41,"status":42,"city":43,"state":11,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"University Hospital Basel","RECRUITING","Basel","4031","Switzerland","CH",{"type":48,"coordinates":49},"Point",[50,51],7.57327,47.55839,{"lat":51,"lon":50},[54,55,59,61,64,65],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},{"name":56,"role":32,"phone":57,"phoneExt":11,"email":58},"Michelle Müller, MD","+41 61 328 55 23","michelle.mueller@usb.ch",{"name":36,"role":60,"phone":11,"phoneExt":11,"email":11},"SUB_INVESTIGATOR",{"name":62,"role":63,"phone":11,"phoneExt":11,"email":11},"Mirjam Christ-Crain, MD","PRINCIPAL_INVESTIGATOR",{"name":31,"role":60,"phone":11,"phoneExt":11,"email":11},{"name":56,"role":60,"phone":11,"phoneExt":11,"email":11},{"type":67,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100620718","plasma-oxytocin-response-to-oral-estrogens-in-healthy-controls-and-avp-deficiency-100620718",false,"NCT07361263","Plasma Oxytocin Response to Oral Estrogens in Healthy Controls and AVP-Deficiency","Plasma Oxytocin in Response to Oral Estradiol Valerate and Ethinylestradiol in Healthy Controls and Patients With AVP-Deficiency","PHOENIX","Inclusion Criteria:\n\nPart 1\n\n1. Adult healthy controls\n2. No medication (including hormonal contraception)\n3. Female patients (except post-menopausal): regular cycle (21-35 days of duration) in the last 6 months\n\nPart 2\n\n1. Confirmed diagnosis of AVP-Deficiency\n2. Age ≥ 18 years\n3. Female patients (except post-menopausal): regular cycle (21-35 days of duration) in the last 6 months or in the case of hormone replacement therapy, with a 1-week pause from the respective treatment\n\nExclusion Criteria:\n\nPart 1\n\n1. Participation in a trial with investigational drugs within 30 days\n2. BMI \\>30\n3. Age \\>50\n4. Illicit substance use (except for cannabis) during the last 30 days\n5. Consumption of alcoholic beverages \\>15 drinks\u002Fweek\n6. Tobacco smoking \\>10 cigarettes\u002Fday\n7. Pregnancy and breastfeeding\n8. Hormonal contraception\n9. Migraine with and without aura\n10. Any cardiometabolic, cardiovascular, and hematological diseases (including deep vein thrombosis\u002Fpulmonary embolism and thrombophilia (DVT\u002FPE))\n11. Active liver dysfunction or alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) levels 2.5 times above the normal range\n12. Diagnosed chronic kidney disease (CKD) \\> grade III (GRF \\\u003C 30ml\u002Fmin)\n\nPart 2\n\n1. Participation in a trial with investigational drugs within 30 days\n2. BMI \\>30\n3. Age \\>50\n4. Illicit substance use (except for cannabis) during the last 30 days\n5. Consumption of alcoholic beverages \\>15 drinks\u002Fweek\n6. Tobacco smoking \\>10 cigarettes\u002Fday\n7. Pregnancy and breastfeeding\n8. Hormonal contraception\n9. Migraine with and without aura\n10. Any cardiometabolic, cardiovascular, and hematological diseases (including DVT\u002FPE and Thrombophilia)\n11. Active liver dysfunction or alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) levels 2.5 times above the normal range\n12. Diagnosed CKD \\> grade III (GRF \\\u003C 30ml\u002Fmin)",true,"ALL","18 Years","50 Years",{"count":81,"type":82},28,"ESTIMATED","INTERVENTIONAL",[85],"NA","The PHOENIX study aims to investigate whether oral estradiol valerate (EV) and ethinylestradiol (EE) can stimulate oxytocin (OXT) and neurophysin-1 (NP-1) release in humans. The goal is to assess their potential as a safe diagnostic stimulation test for oxytocin deficiency, particularly in patients with arginine vasopressin (AVP) deficiency.",[88,89],"AVP Deficiency","Diabetes Insipidus",[91,9,92],"Oxytocin","ethinylestradiol","2026-01-22",{"date":95,"type":96},"2026-01-23","ACTUAL",{"date":98,"type":96},"2026-01-09",{"date":100,"type":82},"2027-02",{"name":5,"class":6},1]